Emergency Use Transparency Act
This bill expands existing statutory provisions requiring the Food and Drug Administration (FDA) to publish notices of authorizations, terminations, or revocations of emergency use authorizations for medical products.
Specifically, the bill requires the FDA to publish such notices on its website. The bill also allows the FDA's disclosures to include a summary of data or information from additional types of submissions.
To amend the Federal Food, Drug, and Cosmetic Act with respect to 
               emergency use authorization transparency.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Emergency Use Transparency Act''.

SEC. 2. INCREASING EUA TRANSPARENCY.

    Section 564(h)(1) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360bbb-3(h)(1)) is amended--
            (1) by inserting ``on the internet website of the Food and 
        Drug Administration and'' after ``promptly publish''; and
            (2) by striking ``application under section 505(i) 512(j), 
        or 520(g), even if such summary may indirectly reveal the 
        existence of such application'' and inserting ``application, 
        request, or submission under this section or section 505(b), 
        505(i), 505(j), 512(b), 512(j), 512(n), 515, 510(k), 513(f)(2), 
        520m(g), 520(m), 571, or 572 of this Act, or section 351(a) or 
        351(k) of the Public Health Service Act, even if such summary 
        may reveal the existence of such an application, request, or 
        submission, or data contained in such application, request, or 
        submission''.
                                 <all>
Emergency Use Transparency Act
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to emergency use authorization transparency.
Emergency Use Transparency Act
Sen. Hassan, Margaret Wood